Drugs / Zinlirvimab
Zinlirvimab
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT05079451 | Jan 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT05612178 | Jul 2023 → Mar 2027 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05245292 | Dec 2022 → Dec 2025 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT04340596 | May 2021 → Jun 2026 overdue | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04811040 | Apr 2021 → Jun 2022 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT04250636 | Oct 2020 → Jan 2022 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT03588715 | Jun 2020 → Dec 2021 | AIDS | Luis Montaner | Unknown | No outcome recorded |
| Phase 1 | NCT03928821 | Jul 2019 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03571204 | Sep 2018 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT03554408 | Jun 2018 → Feb 2021 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT03526848 | Jun 2018 → Sep 2021 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02824536 | Jun 2016 → Jan 2018 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02825797 | Jun 2016 → Aug 2018 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02511990 | Jul 2015 → Dec 2016 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06071767 | Apr 2024 → Apr 2028 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04357821 | Aug 2020 → Jun 2026 overdue | HIV infectious disease | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03707977 | Jun 2019 → Dec 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05729568 | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04720742 | Feb 2021 → Mar 2022 | HIV infectious disease | IrsiCaixa | Withdrawn | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07683000 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07682961 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03831945 Comparator | Apr 2019 → Dec 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07054931 Comparator | Sep 2025 → Oct 2027 expected | HIV infectious disease | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT06205602 Comparator | Jan 2025 → Feb 2029 expected | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Recruiting | No outcome recorded |
| Phase 2 | NCT05300035 Comparator | Apr 2024 → Dec 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 2 | NCT04319367 Comparator | May 2021 → Jul 2027 expected | HIV infectious disease | Imperial College London | Recruiting | No outcome recorded |
| Phase 2 | NCT03837756 Comparator | May 2019 → Jul 2022 | HIV infectious disease | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zinlirvimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07683000 ↗ |
| Known as | 10-1074 | “During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074” NCT04720742 ↗12“single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively)” NCT04357821 ↗ |
| Known as | 10-1074-LS | “Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) at weeks 0, 20 and 40.” NCT05612178 ↗7“Participants were randomly assigned (1:1) to receive two LS-bNAbs (3BNC117-LS and 10-1074-LS) in arm A or saline placebo in arm B” PMID 42202839 ↗ May 2026 “10-1074-LS and 3BNC117-LS” NCT05300035 ↗ |
| Known as | GS-2872 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06071767 ↗ |
| Known as | Monoclonal Antibody 10-1074 | “Monoclonal Antibody 10-1074” NCT02824536 ↗ |
| Action | Inhibit | “suppress viral replication in subjects who are not taking ART” NCT03571204 ↗ |
| Modality | Monoclonal antibody | “10-1074 Monoclonal Antibody” NCT02511990 ↗ |
| Route | Intravenous | “single dose IV administration of 10-1074” NCT02511990 ↗ |